|
Co-founder, President & Chief Executive Officer
Dr. Ojo-Amaize was most recently Director, Cellular Immunology Research at Specialty Laboratories, Inc., a world leader in clinical laboratory testing on normal and aberrant immune responses to diseases. While at Specialty, he developed and patented novel clinical technologies for the diagnosis of aberrant immune responses to silicone in women with silicone breast implants. He previously held a position at ICN Pharmaceuticals, Inc., where he directed the development of novel small molecular weight synthetic nucleosides for immunomodulatory applications. Prior to ICN, Dr. Ojo-Amaize was an NIH Senior Clinical Immunology fellow at the University of California, Los Angeles (UCLA) School of Medicine, where he developed novel technologies to assess the role of antibodies in HIV infection. He has had over twenty years of experience managing the discovery and development of pharmaceuticals and novel diagnostic products enabling life science technologies. Dr. Ojo-Amaize currently serves as a volunteer faculty in the University of Southern California (USC) School of Medicine. He is the author of over 40 publications in peer-reviewed medical journals. Dr. Ojo-Amaize received his B.A. degree in Biology from Prescott College, Prescott, Arizona, a Ph.D. in Cellular Immunology from Uppsala University Biomedical Center, Uppsala, Sweden and a Postdoctoral training in Molecular Immunology from New York University (NYU) School of Medicine, New York, New York. He was the recipient of several prestigious Fellowship Awards including the Rockefeller Foundation, World Health Organization, the National Cancer Institute, and the Swedish Agency for Research and Co-operation with Developing Countries (SAREC). He is a member of the American Association for the Advancement of Science, New York Academy of Sciences, the Scandinavian Society for Immunology, and the Association of Medical Laboratory Immunologists. He is certified as a Laboratory Director in Cellular & Diagnostic Immunology by the New York State Department of Health.
Howard B. Cottam, Ph.D.
Co-founder, Vice President
Dr. Cottam was most recently Director, Medicinal Chemistry, at The Sam and Rose Stein Institute for Research on Aging at the University of California, San Diego, California. He previously held an executive position at ICN Pharmaceuticals, Inc., where he directed the synthesis of novel small molecular weight nucleosides with immunomodulatory, anti-tumor, anti-viral, and/or anti-parasitic properties. Dr. Cottam has served as a consultant to Specialty Laboratories, Inc. and ICN Pharmaceuticals. He is the author of over 40 publications in peer-reviewed medical and chemistry journals. He has had over fifteen years managing the discovery and development of numerous medicinal products. Dr. Cottam received his B.S. degree in Chemistry from Arizona State University in Tempe, Arizona, a Ph.D. in Organic Chemistry from Brigham Young University, and postdoctoral training in Medicinal Chemistry from the Brigham Young University Cancer Research Center.
Emeka J. Nchekwube, M.D.
Medical Director
Dr. Nchekwube currently serves as the Medical Director of IMI and he is also in private practice as a Neurosurgeon. He is on the Board of Directors of several firms including IMI, Providence Farms, Inc., and Beacon Diagnostics. Dr. Nchekwube has had more than twenty years experience in the areas of immunodiagnostics, neurology, and therapeutics. He received his B.S. degree in Chemistry with honors from Central Michigan University, an M.D. from Wayne State University School of Medicine in Detroit, Michigan and residency training in Neurosurgery from Wayne State University. Dr. Nchekwube is an active member of several professional societies, including: American Medical Association, California Medical Association, Congress of Neurological Surgeons and American Association of Neurological Surgeons.
Olusola A. Oyemade, M.D., M.P.H.
Managing Director
Dr. Oyemade currently serves as the Managing Director of IMI and he is also in private practice as a Pediatrician. He is on the Board of Directors of several organizations including IMI, American Academy of Pediatrics, Ch. 2, California, and the Association of Nigerian Physicians in the Americas. He has had more than twenty years experience in the areas of pediatric nephrology and public health. Prior academic positions held include, Assistant Clinical Instructorship at the University of Buffalo, Buffalo, New York, Assistant Professorships in pediatrics at Meharry Medical College, Nashville, Tennessee, Vanderbilt University and Howard University respectively. He received his M.B.; ChB degree from the University of Edinburgh, Edinburgh, Scotland and a Masters of Public Health degree (M.P.H.) from Johns Hopkins University School of Public Health and fellowship training in Pediatric Nephrology from Georgetown University Medical Center and Children's Hospital in Los Angeles. He is a member of the American Academy of Pediatrics and the West African College of Physicians.
Joseph I. Okogun, Ph.D.
Director General, IMI Nigeria, Ltd.
Dr. Okogun was most recently a Consultant Professor of Natural Products Chemistry and Herbal Medicine at the Nigerian National Institute for Pharmaceutical Research and Development (NIPRD). Prior to NIPRD, he was Professor of Organic Chemistry at the University of Ibadan, Nigeria, where he established himself as a world leader in Natural Products Chemistry. He discovered several noted natural products including hypoestoxide, anti-sickling, anti-malarial and anti-convulsion drugs. Dr. Okogun received his B.Sc. degree (with First Class Honors) in Chemistry from the University of Ibadan, Nigeria, a Ph.D. in Chemistry from the University of London (University of Ibadan College of the University of London) and Postdoctoral training in chemistry from Imperial College of Sciences and Technology, London, and Texas A&M under the late Sir Derek Barton, the 1969 Nobel Laureate of Chemistry. He was the recipient of several prestigious fellowship awards including Alexander von Humboldt, Commonwealth Academy, and Tiearzlichen Hochschule, Hanover, Germany. He is on the Board of Directors of IMI Nigeria Ltd, and Bevekt Gedu Chemical Company. He is the author of over seventy publications in peer-reviewed chemistry and Natural products chemistry journals. He is a member of several chemical societies including the Chemical Society of Nigeria, African Academy of Sciences, Nigerian Society of Pharmacognosy, Royal Society of Chemistry (U.K.) and the American Society of Pharmacognosy.
Anthony A. Tiongson, CPA, M.A.
Chief Financial Officer
Mr. Tiongson is currently the Chief Financial Officer for IMI, and is involved in IMI's business development strategies. He also directs his own private financial firm, Anthony A. Tiongson & Associates, where he is President & CEO. Mr. Tiongson has had over forty years of experience in accounting and business management. He received his M.A. degree in business management from the University of Southern California and he is a member of the American Institute of Certified Public Accountants